Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Patient Dosing in Phase II Trial of azficel-T for Chronic Dysphonia Completed Preclinical Toxicology Study for FCX-007 InitiatedPositive POC Data Shows FCX-013 Reduces Dermal Thickness of...
-
RADNOR, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy...
-
PHILADELPHIA and INDIANAPOLIS, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing treatments for infectious diseases including hepatitis B...
-
Deerfield Beach, FL, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Zion Research has published a new report titled “Telemedicine (Tele-Consultation, Tele-Monitoring, Tele-Education, Tele-Training,...
-
MIAMI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Fat blockers work because they have the ability to cling to fat molecules and prevent the body from absorbing some of the fat consumed in the diet, allowing...
-
辛辛那提, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience,...
-
CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan bahawa mereka telah menerima CE Mark bagi illumigene® Malaria, satu ujian baru...
-
CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) anunció hoy que recibió la Marca CE para illumigene® Malaria, una novedosa prueba, de alta...
-
CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) hari ini mengumumkan bahwa perusahaannya telah menerima Tanda CE untuk illumigene® Malaria, sebuah tes...
-
CINCINNATI, Jan. 27, 2016 (GLOBE NEWSWIRE) -- A Meridian Bioscience, Inc. (NASDAQ:VIVO) anunciou hoje que recebeu a Marca CE para o illumigene® Malaria, um teste inovador e altamente...